The contribution of the AT1 receptor to erythropoiesis
Biochemical Pharmacology · 2023
DOI: 10.1016/j.bcp.2023.115805 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023. Verfasst von André F Rodrigues und 1 weiteren Autor:innen. Beteiligte Einrichtung: Max Delbrück Center (MDC), Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany. Electronic address: andre…. Hauptthemen laut MEDLINE: Receptor, Angiotensin, Type 1, Erythropoiesis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: DFG.
Abstract (Originalsprache)
The renin-angiotensin system (RAS) comprises a broad set of functional peptides and receptors that play a role in cardiovascular homeostasis and contribute to cardiovascular pathologies. Angiotensin II (Ang II) is the most potent peptide hormone produced by the RAS due to its high abundance and its strong and pleiotropic impact on the cardiovascular system. Formation of Ang II takes place in the bloodstream and additionally in tissues in the so-called local RAS. Of the two Ang II receptors (AT1 and AT2) that Ang II binds to, AT1 is the most expressed throughout the mammalian body. AT1 expression is not restricted to cells of the cardiovascular system but in fact AT1 protein is found in nearly all organs, hence, Ang II takes part in several modulatory physiological processes one of which is erythropoiesis. In this review, we present multiple evidence supporting that Ang II modulates physiological and pathological erythropoiesis processes trough the AT1 receptor. Cumulative evidence indicates that Ang II by three distinct mechanisms influences erythropoiesis: 1) stimulation of renal erythropoietin synthesis; 2) direct action on bone marrow precursor cells; and 3) modulation of sympathetic nerve activity to the bone marrow. The text highlights clinical and preclinical evidence focusing on mechanistic studies using rodent models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Max Delbrück Center (MDC), Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany. Electronic address: andrefelipe.rodrigues@mdc-berlin.de.
- Max Delbrück Center (MDC), Berlin, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Berlin, Germany; Charité Universitätsmedizin Berlin, Berlin, Germany; Institute for Biology, University of Lübec…
Förderung
- DFG
Zitieren
APA
Rodrigues, A. F., & Bader, M. (2023). The contribution of the AT1 receptor to erythropoiesis. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2023.115805
Vancouver
Rodrigues AF, Bader M. The contribution of the AT1 receptor to erythropoiesis. Biochemical Pharmacology. 2023. doi:10.1016/j.bcp.2023.115805
BibTeX
@article{Rodrigues2023,
author = {Rodrigues, André F and Bader, Michael},
title = {The contribution of the AT1 receptor to erythropoiesis},
journal = {Biochemical Pharmacology},
year = {2023},
doi = {10.1016/j.bcp.2023.115805}
}
EUVIMED